Benjamin E. Turk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Benjamin E. Turk has a total of 345 co-authors. Here are the top co-authors by number of shared publications:
- David A. Calderwood
Department of Pharmacology, Yale University, New Haven, USA
30 shared publications - Hua Jane Lou
Department of Pharmacology, Yale University, New Haven, Connecticut
25 shared publications - Akiko Iwasaki
Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
24 shared publications - Andrew J. Daniels
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut
24 shared publications - Clotilde Huet-Calderwood
Department of Pharmacology, Yale University, New Haven, Connecticut
24 shared publications - Eric Song
Department of Immunobiology, Yale University, New Haven, Connecticut
24 shared publications
Latest Publications
- Open Access
Functional characterization of Rho GTPase activating proteins SYDE1 and SYDE2
The human genome encodes more than 60 proteins containing Rho GTPase activating protein (RhoGAP) domains, many of which remain understudied with respect to their target specificity and biological roles. SYDE1 and SYDE2 are two such orphan RhoGAPs, for which there are few studies characterizing their biochemical and cellular functions and conflicting reports identifying their cognate GTPases. We previously identified SYDE1 and SYDE2 in a screen for substrates of the c-Jun N-terminal kinases. Here, we show that SYDE1 and SYDE2 are preferentially phosphorylated by JNK1 relative to other mitogen-activated protein kinases (MAPKs) at sites proximal to a kinase docking region. Purified SYDE1 and SYDE2 are shown to have significant catalytic GAP activity toward RhoA, Rac1, and Cdc42. However, neither up-nor down-regulation of SYDE1/2 expression leads to detectable changes in bulk GTP loading of any of these GTPases. Nevertheless, we demonstrate that SYDE1 and SYDE2, in a partially GAP-dependent manner, increase cell spreading and number of focal adhesions, and promote more directionally persistent migration in HEK293 cells. Together, these findings establish SYDE1 and SYDE2 as robust JNK substrates with catalytic activity toward a set of Rho GTPases and reveal basic functions of SYDE1 and SYDE2 in regulating cell morphology, adhesion, and migration. One sentence summary: A study of RhoGAPs SYDE1 and SYDE2 reveals their core biochemical and functional characteristics, and establishes their importance in cell morphology, adhesion, and migration.
Open AccessFunctional characterization of Rho GTPase activating proteins SYDE1 and SYDE2
The human genome encodes more than 60 proteins containing Rho GTPase activating protein (RhoGAP) domains, many of which remain understudied with respect to their target specificity and biological roles. SYDE1 and SYDE2 are two such orphan RhoGAPs, for which there are few studies characterizing their biochemical and cellular functions and conflicting reports identifying their cognate GTPases. We previously identified SYDE1 and SYDE2 in a screen for substrates of the c-Jun N-terminal kinases. Here, we show that SYDE1 and SYDE2 are preferentially phosphorylated by JNK1 relative to other mitogen-activated protein kinases (MAPKs) at sites proximal to a kinase docking region. Purified SYDE1 and SYDE2 are shown to have significant catalytic GAP activity toward RhoA, Rac1, and Cdc42. However, neither up-nor down-regulation of SYDE1/2 expression leads to detectable changes in bulk GTP loading of any of these GTPases. Nevertheless, we demonstrate that SYDE1 and SYDE2, in a partially GAP-dependent manner, increase cell spreading and number of focal adhesions, and promote more directionally persistent migration in HEK293 cells. Together, these findings establish SYDE1 and SYDE2 as robust JNK substrates with catalytic activity toward a set of Rho GTPases and reveal basic functions of SYDE1 and SYDE2 in regulating cell morphology, adhesion, and migration. One sentence summary: A study of RhoGAPs SYDE1 and SYDE2 reveals their core biochemical and functional characteristics, and establishes their importance in cell morphology, adhesion, and migration.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Differential expression of SKO vs YRG cells ± IFNAR blockade by RNAseq.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Differential expression of SKO vs YRG cells ± IFNAR blockade by RNAseq.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Summary of exonic mutations in YRG cells compared with YMG and WT C57BL6/J cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Summary of exonic mutations in YRG cells compared with YMG and WT C57BL6/J cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Differential expression of SKO vs YRG cells, by RNAseq.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Differential expression of SKO vs YRG cells, by RNAseq.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S2: CRISPR screen guide distributions, related to Figure 1
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S2: CRISPR screen guide distributions, related to Figure 1
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S1: Experimental validation of SETDB1 knockout and flow gating schemes, related to Figure 4
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S1: Experimental validation of SETDB1 knockout and flow gating schemes, related to Figure 4
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S6: Characterization of possible SKO tumor antigens, related to Figure 4.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S6: Characterization of possible SKO tumor antigens, related to Figure 4.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
List of primers used to perform RT-qPCR on YUDOSO cells related to Figure S6.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
List of primers used to perform RT-qPCR on YUDOSO cells related to Figure S6.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S5: Evaluation of SETDB1 knockdown in human melanoma cells, related to Figure 4:
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S5: Evaluation of SETDB1 knockdown in human melanoma cells, related to Figure 4:
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S4: Evaluation of differences in SKO tumor gene expression and microenvironment profiles, related to Figure 3:
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S4: Evaluation of differences in SKO tumor gene expression and microenvironment profiles, related to Figure 3: